Answers are grounded in this paper and cite their sources.
AIMS: To evaluate serum isatin, an endogenous stress-responsive indole, as a diagnostic, pharmacodynamic and prognostic biomarker in major depressive disorder (MDD), seizures and schizophrenia. PATIENTS AND METHODS: In this prospective observational study, 120 participants (30 each with MDD, seizures or schizophrenia, and 30 healthy controls) were enrolled. Serum isatin was measured by HPLC at baseline and, in patients, after 12 weeks of standard pharmacotherapy. CONCLUSION: Serum isatin shows promise as a transdiagnostic pharmacodynamic biomarker and as a prognostic marker in seizures, with its change being more informative than absolute levels. Validation in larger, multicentre longitudinal studies is needed before clinical use.
No takes yet. Share an insight, caveat, or question.
Hota et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: